Molecular characterization of antigen-peptide pulsed dendritic cells: Immature dendritic cells develop a distinct molecular profile when pulsed with antigen peptide

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Yang, Amy X ^a   Chong, Numju ^b   Jiang, Yufei ^b   Catalano, Jennifer ^a   Puri, Raj K ^a   Khleif, Samir N ^b,c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH PROTEIN 61; EPHRIN RECEPTOR A1; HLA A2 ANTIGEN; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; PROSTAGLANDIN F; PROTEIN E7; THIOREDOXIN REDUCTASE 1;

ANTIGEN BINDING; ARTICLE; BTG1 GENE; CELL ADHESION; CELL DIFFERENTIATION; CELL ELONGATION; CELL FUNCTION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; CYR61 GENE; DENDRITIC CELL; DNA REPAIR; EPHA1 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IGFBP3 GENE; IGSF6 GENE; IL8 GENE; IMMUNE RESPONSE; IN VITRO STUDY; KPNA7 GENE; MICROARRAY ANALYSIS; NCR3 GENE; NFKBIA GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD STEM CELL; PGF GENE; PHENOTYPE; POLYMERASE CHAIN REACTION; QUALITATIVE ANALYSIS; SEMA6A GENE; SRGN GENE; TRANSCRIPTION REGULATION; TREM2 GENE; TUBAL3 GENE; UPREGULATION;

ANTIGEN PRESENTATION; DENDRITIC CELLS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HLA-A2 ANTIGEN; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOTHERAPY; MICROARRAY ANALYSIS; PAPILLOMAVIRUS E7 PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84899903639     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086306     Document Type: Article

References (26)

1. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252. (Pubitemid 28155090)
2. Soumelis V, Liu YJ (2006) From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur J Immunol 36: 2286-2292. (Pubitemid 44420583)
3. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296-306. (Pubitemid 40516155)
4. Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104: 599-613.
5. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179: 1109-1118.
6. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J (1992) GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360: 258-261.
7. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, et al. (1997) Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27: 3135-3142. (Pubitemid 28018007)
8. Han TH, Jin P, Ren J, Slezak S, Marincola FM, et al. (2009) Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J Immunother 32: 399-407.
9. Tsukui T, Hildesheim A, Schiffman MH, Lucci J, 3rd, Contois D, et al. (1996) Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res 56: 3967-3974. (Pubitemid 26284746)
10. Lindstedt M, Johansson-Lindbom B, Borrebaeck CA (2002) Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators. Int Immunol 14: 1203-1213. (Pubitemid 35175227)
11. Le Naour F, Hohenkirk L, Grolleau A, Misek DE, Lescure P, et al. (2001) Profiling changes in gene expression during differentiation and maturation of monocyte-derived dendritic cells using both oligonucleotide microarrays and proteomics. J Biol Chem 276: 17920-17931.
12. Dietz AB, Bulur PA, Knutson GJ, Matasic R, Vuk-Pavlovic S (2000) Maturation of human monocyte-derived dendritic cells studied by microarray hybridization. Biochem Biophys Res Commun 275: 731-738.
13. Moschella F, Maffei A, Catanzaro RP, Papadopoulos KP, Skerrett D, et al. (2001) Transcript profiling of human dendritic cells maturation-induced under defined culture conditions: comparison of the effects of tumour necrosis factor alpha, soluble CD40 ligand trimer and interferon gamma. Br J Haematol 114: 444-457. (Pubitemid 32762249)
14. Tureci O, Bian H, Nestle FO, Raddrizzani L, Rosinski JA, et al. (2003) Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis. FASEB J 17: 836-847. (Pubitemid 36538659)
15. Messmer D, Messmer B, Chiorazzi N (2003) The global transcriptional maturation program and stimuli-specific gene expression profiles of human myeloid dendritic cells. Int Immunol 15: 491-503. (Pubitemid 36432402)
16. McIlroy D, Tanguy-Royer S, Le Meur N, Guisle I, Royer PJ, et al. (2005) Profiling dendritic cell maturation with dedicated microarrays. J Leukoc Biol 78: 794-803. (Pubitemid 41292103)
17. Cools N, Ponsaerts P, Lenjou M, Nijs G, Van Bockstaele DR, et al. (2006) Sensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8+ T cells with peptidepulsed autologous dendritic cells. Mol Cancer 5: 49.
18. Yang AX, Mejido J, Bhattacharya B, Petersen D, Han J, et al. (2006) Analysis of the quality of contact-pin fabricated oligonucleotide microarrays. Mol Biotechnol 34: 303-315. (Pubitemid 46220190)
19. Han J, Lee H, Nguyen NY, Beaucage SL, Puri RK (2005) Novel multiple 59-amino-modified primer for DNA microarrays. Genomics 86: 252-258. (Pubitemid 40917229)
20. Jin P, Han TH, Ren J, Saunders S, Wang E, et al. (2010) Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 8: 4.
21. Murakami M, Gurski KJ, Marincola FM, Ackland J, Steller MA (1999) Induction of specific CD8+ T-lymphocyte responses using a human papilloma-virus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 59: 1184-1187. (Pubitemid 29136243)
22. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, et al. (1999) Induction of human papillomavirus-specific CD4 (+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 73: 5402-5410. (Pubitemid 29274822)
23. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, et al. (2008) Induction of tumor-specific CD4 + and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14: 178-187. (Pubitemid 351377994)
24. Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FG, et al. (2005) Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 175: 1628-1635. (Pubitemid 41023065)
25. Cascio S, Zhang L, Finn OJ (2011) MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-kappaB p65 and binding to cytokine promoters: importance of extracellular domain. J Biol Chem 286: 42248-42256.
26. Beatty P, Ranganathan S, Finn OJ (2012) Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology 1: 263-270.